DYAINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
DYADIC INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.03 (-7.35%)
Close on Oct 19, 2026
- Market cap
- $13.88M
- P/E (TTM)
- –
- Dividend yield
- –
DYADIC INTERNATIONAL INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant [Member] | $2.47M | $2.13M | $1.86M | – | – | – | – | – | – | – | – | – | 64.9% | – |
| License [Member] | $235.00K | $485.00K | $265.00K | – | – | – | $890.17K | $1.65M | $264.71K | $308.82K | $352.94K | $176.47K | 6.2% | – |
| Research And Development [Member] | – | – | $967.31K | $1.10M | $1.28M | $1.45M | $1.61M | $1.72M | $1.54M | $1.95M | $2.55M | $2.78M | – | – |
By region
From the segment and revenue-disaggregation notes of Dyadic International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.